RAPT Therapeutics, Inc. (RAPT)
Automate Your Wheel Strategy on RAPT
With Tiblio's Option Bot, you can configure your own wheel strategy including RAPT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RAPT
- Rev/Share 0.0
- Book/Share 6.1005
- PB 1.5654
- Debt/Equity 0.0192
- CurrentRatio 13.253
- ROIC -0.6747
- MktCap 157935990.0
- FreeCF/Share -3.408
- PFCF -1.7196
- PE -2.4169
- Debt/Assets 0.0177
- DivYield 0
- ROE -0.6791
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | RAPT | JP Morgan | Underweight | Neutral | -- | $14 | July 30, 2025 |
| Resumed | RAPT | H.C. Wainwright | -- | Buy | -- | $6 | May 22, 2025 |
| Upgrade | RAPT | H.C. Wainwright | Neutral | Buy | -- | $10 | Dec. 26, 2024 |
News
Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
After reaching an important support level, Rapt Therapeutics (RAPT) could be a good stock pick from a technical perspective. RAPT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Read More
Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 122.2% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Best Momentum Stocks to Buy for July 15th
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
FUTU, IVZ and RAPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2025.
Read More
Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at an 183.8% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company's lead product candidate RPT904, is a novel, half-life extended monoclonal antibody designed to …
Read More
Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 282.7% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
About RAPT Therapeutics, Inc. (RAPT)
- IPO Date 2019-10-31
- Website https://www.rapt.com
- Industry Biotechnology
- CEO Brian Russell Wong
- Employees 67